Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Single-Arm, Phase 2 Trial
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Carboplatin (Primary) ; Olaparib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 14 Nov 2023 Planned End Date changed from 28 Feb 2027 to 30 Nov 2026.
- 14 Nov 2023 Planned primary completion date changed from 28 Feb 2026 to 30 Nov 2025.
- 14 Nov 2023 Status changed from recruiting to active, no longer recruiting.